J&J's Long-Term Data Shows High Remission Rates for Crohn’s Disease Patients on Tremfya
Johnson & Johnson (ticker: JNJ) has released long-term data from two phase 3 trials, GALAXI 2 and GALAXI 3, showing that patients with Crohn's disease treated with its drug Tremfya achieved clinical remission rates of up to 94% over three years. The results highlight the sustained efficacy of guselkumab in managing this chronic inflammatory condition. The data comes from a follow-up analysis where participants received induction therapy followed by maintenance treatment, demonstrating that high levels of disease control can be maintained long-term with Tremfya. These findings could reinforce J&J's position in the biologics market for gastrointestinal disorders and potentially influence prescribing patterns among gastroenterologists. The positive results may also support future regulatory or reimbursement decisions and provide a competitive edge over other therapies currently available.
Tickers: $JNJ
Topics: clinical remission Crohn's disease phase 3 trials Tremfya (guselkumab)